ArticleGHM open2021
Seroprevalence of antibodies against SARS-CoV-2 among workers in a national research institute and hospital in Central Japan.
Article in GHM open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immune responses to COVID-19 vaccine BNT162b2 in workers at a research institute in Japan: 6-month follow-up survey.The Journal of infection · 2022Article
- Prevalence of SARS-CoV-2 antibodies after one-year follow up among workers in a research institute in Japan.The Journal of infection · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To achieve effective prevention and control strategies for COVID-19, regular survey of seroprevalence of antibodies against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is essential. Using four serological tests, we examined the residual sera collected in an annual medical checkup of the staff members of the National Center for Geriatrics and Gerontology in Aichi Prefecture, Central Japan in June 2020. Of the 631 samples, two were positive for anti-SARS-CoV-2 antibodies in at least two tests, showing a seroprevalence of 0.32%. Four subjects showed positive results in only one test. All individuals were asymptomatic and had not been in close contact with patients diagnosed with COVID-19. Multiple antibody tests could be used to assess the prevalence of SARS-CoV-2 infection including individuals without COVID-19 symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.